AGC Biologics Expands In Denmark

The strategic expansion of the Copenhagen facility will meet increasing global demand for biopharmaceutical development and manufacturing.


https://businessfacilities.com/2018/08/agc-biologics-expands-copenhagen-denmark/
The strategic expansion of the Copenhagen facility will meet increasing global demand for biopharmaceutical development and manufacturing.
Facebooktwittergoogle_plusredditpinterestlinkedintumblrmail

AGC Biologics Expands In Denmark

The strategic expansion of the Copenhagen facility will meet increasing global demand for biopharmaceutical development and manufacturing.

AGC Biologics Expands In Denmark

As part of its global expansion strategy, AGC Biologics is increasing manufacturing capacity at its Copenhagen, Denmark facility. AGC Biologics is a global leader in clinical and commercial manufacturing of therapeutic proteins.AGC Biologics Copenhagen Denmark

The Copenhagen facility will add a Single-use Bioreactor (SUB) 6Pack™ suite, consisting of six 2000L production bioreactors and a 2000L seed train. The addition of this proprietary bioreactor configuration will enable more flexible, innovative and customized cGMP production capabilities, offering scales from 2000L to 12000L within a single run. The six bioreactors will be run in single unit operations or in groups; simultaneously, sequentially or staggered; to meet each client’s specific production needs.

The expansion also includes additional capabilities for harvesting, purification, buffer and media production that will support the processing of different therapeutic proteins, including high antibody titer processes. The new suites are scheduled to be online in November 2018, and are expected to support the manufacturing of several commercial products.

AGC Biologics Copenhagen Denmark“We’re very pleased to implement this important capital expansion that addresses our clients’ evolving needs for increased capacity and customization in development and production,” said Gustavo Mahler, Ph.D., President and Chief Executive Officer of AGC Biologics. “The investment in our Copenhagen site enables AGC Biologics to offer more production capabilities within accelerated timelines, while continuing to provide our deep industry expertise, continuous innovation and proven technical excellence.”

AGC Biologics currently employs more than 850 employees worldwide. The company’s network spans three continents, with cGMP-compliant facilities in Seattle, WA; Berkeley, CA; Copenhagen, Denmark; Heidelberg, Germany; Yokohama, Japan; and Chiba, Japan.

AGC Biologics offers deep industry expertise and unique customized services for the scale-up and cGMP manufacture of protein-based therapeutics; from pre-clinical to commercial production, for mammalian and microbial. Integrated service offerings include cell line development, bioprocess development, formulation, analytical testing, antibody drug development and conjugation, cell banking and storage, and protein expression — including the proprietary CHEF1® Expression System for mammalian production.

Suggested Links:

You Might Like:

LEAVE A REPLY